A biotech stock doubled after it got positive results on a drug to tackle the leading cause of infectious death in the US
The clinical trial - the first of two late-stage studies - showed that the company's drug, lefamulin, was as effective as the commonly used antibiotic moxifloxacin, which was the main goal of the trial.
Community-acquired bacterial pneumonia is one of the most common infectious diseases and the leading cause of infectious death in the United States.
The company's shares jumped to as much as $13.91 in premarket trading from their Friday close of $6.86.
Markets Insider
Why new antibiotics are critical
Antibiotic-resistant diseases are expected to kill 10 million people annually by 2050. And it hasn't been easy to get new drugs to stay ahead of the problem, especially for common infections like pneumonia. Many major pharmaceutical companies have stopped developing new antibiotics, and the drugs that are still in development have faced numerous stumbling blocks toward approval.
Government organizations such as the Centers for Disease Control and Prevention have been warning about the rise of antibiotic resistance, saying we'll soon be in a "post-antibiotic era."
Should the second of Nabriva's two late-stage trials pan out and lefamulin gets approved, it could give doctors a new line of treatment to stay ahead of that age.
Reuters reporting by Manas Mishra.
- I quit McKinsey after 1.5 years. I was making over $200k but my mental health was shattered.
- Some Tesla factory workers realized they were laid off when security scanned their badges and sent them back on shuttles, sources say
- I tutor the children of some of Dubai's richest people. One of them paid me $3,000 to do his homework.
- Why are so many elite coaches moving to Western countries?
- Global GDP to face a 19% decline by 2050 due to climate change, study projects
- 5 things to keep in mind before taking a personal loan
- Markets face heavy fluctuations; settle lower taking downtrend to 4th day
- Move over Bollywood, audio shows are starting to enter the coveted ‘100 Crores Club’